Investment Column: Halma's premium valuation is deserved


Halma

Our view: hold

Share price: 418.5p (-8.2p)

When you're at work there's a good chance that equipment made by Halma, one of those under-reported British success stories, is what will keep you safe.

If you invest your money with the company, that should be pretty safe too, at least if the business continues down the path it has taken.

We tipped Halma, which provides a wide range of safety equipment including hazard detectors and sensors, as a buy at 275.5p in June. Since then, the shares have been rock-solid performers, more than justifying our faith.

The company's recent results provided further evidence of a business in rude health. Profits were up a fifth at £98m on revenues of £518m, up 13 per cent, while the dividend was raised by 7 per cent. Yesterday saw Halma sealing a £5.6m deal to buy Avo Photonics, a US company that makes advanced, miniaturised photonic components and will join Halma's health and analysis operations.

The company has promised more deals, but this shouldn't worry shareholders – it has focused on profitable, largely privately owned firms that can complement and enhance existing Halma businesses. Big, transformative transactions beloved of fee-chasing investment bankers, and few others, are not on the agenda.

With a rapidly growing Asian franchise – where fast-growing economies are increasingly paying heed to worker protection along Western lines – the signs all look good.

Trouble is, the market has well and truly woken up to the stock's attractions. In fact, at 15 times forecast full-year earnings, it now trades at a significant premium to its sector. Moreover, that premium is rising.

But while taking profits might be tempting, we think that would be a mistake. While the shares are probably fairly valued, Halma's fundamentals are solid, it has good growth prospects and its track record justifies a higher valuation than its peers'. This one will pay off for those who keep hold over the long term.



Bglobal

Our view: speculative buy

Share price: 14.5p (+0.25p)

Bglobal's share price has been under the cosh recently, and on the face of it you might ask why.

After all, the company yesterday announced that revenues for the year ending 31 March had more than doubled to £29m while an adjusted pre-tax loss of nearly £500,000 in the preceding year had morphed into a healthy £3.8m profit.

The issue is that this profit is likely to be a high point, at least for the next couple of years.

Bglobal provides smart energy meters. These are a good idea – they make the sporadic, and sometimes inaccurate, meter readings that consumers are used to a thing of the past.

Naturally, since being presented with such a no-brainer, the Government has been dragging its feet. A nationwide roll-out is now targeted for 2014 but analysts fear more delays. Which means energy providers have put their own plans on hold, making life difficult for Bglobal.

Happily, with efforts to bring new entrants into the energy market, there is an opportunity for the company to jump in and offer services such as billing, data collection, and the like.

It has already helped Co-op into the market and others could follow. Backing the shares now is risky, but they're cheap and the company is financially strong, with £4m in net cash at the bank. One for investors willing to speculate.

Dechra Pharmaceuticals

Our view: buy

Share price: 485.75p (-18.25p)

Dechra has been one of our favoured stocks for some time now, putting out good updates even as other companies battled with sluggish trends in the wider economy.

Yesterday was no different. The veterinary products group issued a trading update ahead of its full-year figures in September, with the board saying that "although economic conditions have had an impact on our markets, the group has performed in line with our expectations and made solid progress in the financial year."

The US business is performing strongly, net debt is down and group revenues are up. They are also up in Europe. Moreover, at under 14 times forward earnings for this year and around 11 times on the estimates for next year, the valuation also remains attractive. We said buy at 445p in September. Although the stock is up nicely since then, we're confident that there is more to come.

Start your day with The Independent, sign up for daily news emails
News
ebooksAn unforgettable anthology of contemporary reportage
Life and Style
Angel Di Maria is shown the red card
tech
Sport
Roger Federer after his win over Tomas Berdych
sport
Life and Style
News in briefs: big pants in 'Bridget Jones's Diary'
fashionBig knickers are back
Sport
James Milner is set to sign for Liverpool this week despite rival interest from Arsenal
sportReds baulk at Benteke £32.5m release clause
News
The controversial Motor Neurone Disease Association poster, featuring sufferer Michael Smith, has drawn a series of angry complaints
newsThis one has been criticised for its 'threatening tone'
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Recruitment Genius: Financial Reporting Manager

£70000 - £90000 per annum: Recruitment Genius: A Financial Reporting Manager i...

Recruitment Genius: Payments Operations Assistant

£23000 - £25000 per annum: Recruitment Genius: They win lots of awards for the...

Recruitment Genius: Telephone Debt Negotiator

£13500 - £20000 per annum: Recruitment Genius: This nationwide enforcement com...

Guru Careers: Communications Exec / PR Exec

£25 - £30K: Guru Careers: We are seeking a highly-motivated and ambitious Comm...

Day In a Page

On your feet! Spending at least two hours a day standing reduces the risk of heart attacks, cancer and diabetes, according to new research

On your feet!

Spending half the day standing 'reduces risk of heart attacks and cancer'
Liverpool close in on Milner signing

Liverpool close in on Milner signing

Reds baulk at Christian Benteke £32.5m release clause
With scores of surgeries closing, what hope is there for the David Cameron's promise of 5,000 more GPs and a 24/7 NHS?

The big NHS question

Why are there so few new GPs when so many want to study medicine?
Big knickers are back: Thongs ain't what they used to be

Thongs ain't what they used to be

Big knickers are back
Thurston Moore interview

Thurston Moore interview

On living in London, Sonic Youth and musical memoirs
In full bloom

In full bloom

Floral print womenswear
From leading man to Elephant Man, Bradley Cooper is terrific

From leading man to Elephant Man

Bradley Cooper is terrific
In this the person to restore our trust in the banks?

In this the person to restore our trust in the banks?

Dame Colette Bowe - interview
When do the creative juices dry up?

When do the creative juices dry up?

David Lodge thinks he knows
The 'Cher moment' happening across fashion just now

Fashion's Cher moment

Ageing beauty will always be more classy than all that booty
Thousands of teenage girls enduring debilitating illnesses after routine school cancer vaccination

Health fears over school cancer jab

Shock new Freedom of Information figures show how thousands of girls have suffered serious symptoms after routine HPV injection
Fifa President Sepp Blatter warns his opponents: 'I forgive everyone, but I don't forget'

'I forgive everyone, but I don't forget'

Fifa president Sepp Blatter issues defiant warning to opponents
Extreme summer temperatures will soon cause deaths of up to 1,700 more Britons a year, says government report

Weather warning

Extreme summer temperatures will soon cause deaths of up to 1,700 more Britons a year, says government report
LSD: Speaking to volunteer users of the drug as trials get underway to see if it cures depression and addiction

High hopes for LSD

Meet the volunteer users helping to see if it cures depression and addiction
German soldier who died fighting for UK in Battle of Waterloo should be removed from museum display and given dignified funeral, say historians

Saving Private Brandt

A Belgian museum's display of the skeleton of a soldier killed at Waterloo prompts calls for him to be given a dignified funeral